… been a couple of weeks now since Dendreon ( DNDN ) reported an absolute train wreck ..... analyst community has said about Dendreon recently. One thing is certain ..... future. A recap of Q1 results: Dendreon reported a revenue drop of more …
Dendreon Corp . ( DNDN ) Bank of America Merrill Lynch 2013 Healthcare ..... next speaker, Greg Schiffman, CFO of Dendreon . I am looking forward for the update ..... and uncertainties defined more about Dendreon ’s specific risks and uncertainties …
By Amy Baldwin : During Dendreon 's ( DNDN ) two year 90% loss there ..... year-over-year loss in Provenge sales and a financial position that continues to worsen, Dendreon could be headed lower and ..... Goals that May Not be Reached Dendreon has fallen after reporting …
… Thursday morning, biotech darling Dendreon ( DNDN ) reported its fiscal first quarter earnings report . The quarter for Dendreon was absolutely dreadful. Revenues ..... terrible quarter, and analyze whether Dendreon is finished. Q1 results: Total …
… By Brian L. Wilson : Today Dendreon (NASDAQ: DNDN ) shocked the market after ..... disappointing $67.6 M in Provenge ( sipuleucel-T ) sales for ..... shareholders were clearly looking for Provenge sales growth to offset the ..... the data is alarming. Dendreon is continuing its efforts …
Dendreon ( DNDN -14.4% ) retests its lows for the day as ..... begins to weigh in on its Q1 miss and dismal Provenge sales numbers. Stifel Nicolaus cuts the shares to Sell, calling Provenge "hopeless," and saying the company is likely …
Dendreon Corporation ( DNDN ) Q1 2013 Earnings Call May 01, 2013 ..... welcome to the first quarter 2013 Dendreon earnings conference call. At this ..... seekingalpha.com/article/1419181- dendreon -s-ceo-discusses-q1-2013 …
… I alerted readers to the fact that sequencing Dendreon 's ( DNDN ) Provenge after Medivation's ( MDVN ) Xtandi produced startling ..... rise again. Subsequently, he was infused with Provenge in July 2010 while continuing on Xtandi. Six months …
In its call earlier, Dendreon ( DNDN -12% ) CEO John Johnson ..... attributed its big Q1 miss on Provenge sales to increased competition ..... injectable therapies like DNDN 's. But the veracity ..... more closely linked to DNDN 's sizeable chunk of …
May 9 (Reuters) - Biotechnology drugs maker Dendreon Corp , which has been struggling with slow sales of its prostate cancer vaccine Provenge , reported lower quarterly sales of the vaccine.